Anne-Michelle Noone1, Ruth M Pfeiffer2, Joanne F Dorgan3, Laurence S Magder3, Jonathan S Bromberg4, Charles F Lynch5, Cyllene R Morris6, Karen S Pawlish7, Eric A Engels2. 1. Divison of Cancer Control and Population Sciences, National Cancer Institute, Bethesda, Maryland. 2. Divison of Cancer Epidemiology and Genetics, National Cancer Institute, Bethesda, Maryland. 3. Department of Epidemiology and Public Health, University of Maryland School of Medicine, Baltimore, Maryland. 4. Department of Surgery, University of Maryland School of Medicine, Baltimore, Maryland. 5. Department of Epidemiology, University of Iowa, Iowa City, Iowa. 6. Institute for Population Health Improvement, UC Davis Health System, Sacramento, California. 7. Cancer Epidemiology Services, New Jersey Department of Health, Trenton, New Jersey.
Abstract
BACKGROUND: Solid organ transplant recipients have an elevated risk of cancer. Quantifying deaths attributable to cancer can inform priorities to reduce cancer burden. METHODS: Linked transplantation and cancer registry data were used to identify incident cancers and deaths among solid organ transplant recipients in the United States (1987-2014). Population-attributable fractions (PAFs) of deaths due to cancer and corresponding cancer-attributable mortality rates were estimated using Cox models. RESULTS: Among 221,962 solid organ transplant recipients, 15,012 developed cancer. Approximately 13% of deaths (PAF, 13.2%) were attributable to cancer, corresponding to a cancer-attributable mortality rate of 516 per 100,000 person-years. Lung cancer was the largest contributor to mortality (PAF, 3.1%), followed by non-Hodgkin lymphoma (NHL; PAF, 1.9%), colorectal cancer (PAF, 0.7%), and kidney cancer (PAF, 0.5%). Cancer-attributable mortality rates increased with age at transplantation, reaching 1229 per 100,000 person-years among recipients aged ≥65 years. NHL was the largest contributor among children (PAF, 4.1%) and lung cancer was the largest contributor among recipients aged ≥50 years (PAFs, 3.7%-4.3%). Heart recipients had the highest PAF (16.4%), but lung recipients had the highest cancer-attributable mortality rate (1241 per 100,000 person-years). Overall, mortality attributable to cancer increased steadily with longer time since transplantation, reaching 15.7% of deaths (810 per 100,000 person-years) at ≥10 years after transplantation. Comparison of cancer-attributable mortality rates with specified causes of death indicated that some deaths recorded as other causes might instead be caused by cancer or its treatment. CONCLUSIONS: Cancer is a substantial cause of mortality among solid organ transplant recipients, with major contributions reported from lung cancer and NHL. Cancer-attributable mortality increases with age and time since transplantation, and therefore cancer deaths will become an increasing burden as recipients live longer.
BACKGROUND: Solid organ transplant recipients have an elevated risk of cancer. Quantifying deaths attributable to cancer can inform priorities to reduce cancer burden. METHODS: Linked transplantation and cancer registry data were used to identify incident cancers and deaths among solid organ transplant recipients in the United States (1987-2014). Population-attributable fractions (PAFs) of deaths due to cancer and corresponding cancer-attributable mortality rates were estimated using Cox models. RESULTS: Among 221,962 solid organ transplant recipients, 15,012 developed cancer. Approximately 13% of deaths (PAF, 13.2%) were attributable to cancer, corresponding to a cancer-attributable mortality rate of 516 per 100,000 person-years. Lung cancer was the largest contributor to mortality (PAF, 3.1%), followed by non-Hodgkin lymphoma (NHL; PAF, 1.9%), colorectal cancer (PAF, 0.7%), and kidney cancer (PAF, 0.5%). Cancer-attributable mortality rates increased with age at transplantation, reaching 1229 per 100,000 person-years among recipients aged ≥65 years. NHL was the largest contributor among children (PAF, 4.1%) and lung cancer was the largest contributor among recipients aged ≥50 years (PAFs, 3.7%-4.3%). Heart recipients had the highest PAF (16.4%), but lung recipients had the highest cancer-attributable mortality rate (1241 per 100,000 person-years). Overall, mortality attributable to cancer increased steadily with longer time since transplantation, reaching 15.7% of deaths (810 per 100,000 person-years) at ≥10 years after transplantation. Comparison of cancer-attributable mortality rates with specified causes of death indicated that some deaths recorded as other causes might instead be caused by cancer or its treatment. CONCLUSIONS: Cancer is a substantial cause of mortality among solid organ transplant recipients, with major contributions reported from lung cancer and NHL. Cancer-attributable mortality increases with age and time since transplantation, and therefore cancer deaths will become an increasing burden as recipients live longer.
Authors: Meredith S Shiels; James J Goedert; Richard D Moore; Elizabeth A Platz; Eric A Engels Journal: Cancer Epidemiol Biomarkers Prev Date: 2010-09-13 Impact factor: 4.254
Authors: Yun Miao; Jason J Everly; Thomas G Gross; Amit D Tevar; M Roy First; Rita R Alloway; E Steve Woodle Journal: Transplantation Date: 2009-05-15 Impact factor: 4.939
Authors: Isabel Fernández-Carrera González; Christian Ibarra Estupiñan; Irene Rivero Fernández; Marta Sanz Rodríguez; Esther García González; Carlos Almodóvar Álvarez; Javier Gavilanes-Plasencia Journal: Eur Arch Otorhinolaryngol Date: 2020-06-19 Impact factor: 2.503
Authors: Andreas Søborg; Joanne Reekie; Allan Rasmussen; Caspar Da Cunha-Bang; Finn Gustafsson; Kasper Rossing; Michael Perch; Paul Suno Krohn; Søren Schwartz Sørensen; Thomas Kromann Lund; Vibeke Rømming Sørensen; Christina Ekenberg; Louise Lundgren; Isabelle Paula Lodding; Kasper Sommerlund Moestrup; Jens Lundgren; Neval Ete Wareham Journal: PLoS One Date: 2022-07-25 Impact factor: 3.752
Authors: Felix Becker; Anne-Sophie Mehdorn; Vasilios Getsopulos; Katharina Schütte-Nütgen; Stefan Reuter; Barbara Suwelack; Andreas Pascher; Jens G Brockmann; Ralf Bahde Journal: J Clin Med Date: 2021-05-27 Impact factor: 4.241